<DOC>
	<DOCNO>NCT01858831</DOCNO>
	<brief_summary>This study single-center , phase I , randomize , open , fed condition , parallel , single dose study evaluate pharmacokinetics safety , tolerability Atovaquone/proguanil combination tablet atovaquone suspension Japanese healthy male subject . Serial blood sample collect determination plasma concentration atovaquone , proguanil cycloguanil dose atovaquone 1000mg/proguanil 400 mg plasma atovaquone concentration atovaquone 750 1500 mg. Safety assessment perform treatment group . CYP2C19 contribute proguanil metabolism . CYP2C19 genotype determine atovaquone/proguanil dose group .</brief_summary>
	<brief_title>Single Oral Dose Study Atovaquone/Proguanil Hydrochloride Combination Tablets Atovaquone Suspension</brief_title>
	<detailed_description />
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Atovaquone , proguanil drug combination</mesh_term>
	<criteria>Healthy define free clinically significant illness disease determine responsible experienced physician , base medical evaluation include medical history , physical examination , vital sign , laboratory test ECG . Japanese healthy male 20 55 year age inclusive , time signing informed consent . Body weight = &gt; 50 kg BMI within range 18.5 25 kg/m2 Nonsmoker exsmoker cease smoke least 6 month . ( inclusive ) . ALT , alkaline phosphatase bilirubin upper limit normal ( ULN ) Single QTcB &lt; 450 msec . Vital sign within follow range ; Systolic blood pressure : &lt; 90 mmHg &gt; 140 mmHg , Diastolic blood pressure : &lt; 45 mmHg &gt; 90 mmHg , Plus rate : &lt; 45 bpm &gt; 100 bpm , Body temperature : 37.5 C Capable give write informed consent , include compliance requirement restriction list consent form . A positive result syphilis , HBs antigen , HCV antibody , HIV antibody HTLV1 antibody time screen . History cardiac disease irrespective without symptom . An episode cardiac syncope within one year screening period . History/evidence clinically significant pulmonary disease hyper/hypothyroidism . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug screen . History regular alcohol consumption exceed , average , 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 350 mL beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screen . The subject participate clinical study postmarketing study investigational noninvestigational product previous 4 month precede administration study medication study . The subject participate clinical study postmarketing study investigational noninvestigational product previous 4 month precede administration study medication study . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use alcohol , prescription nonprescription drug , include vitamin , herbal dietary supplement within 14 day 5 halflives ( whichever longer ) prior first dose study medication . History sensitivity study medication , component thereof history drug allergy exclude pollen allergy without current symptom . Where participation study would result donation blood blood product excess 400 mL within 4 month 200 mL within 2 month . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>